• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

RB/E2F1作为晚期疾病中癌细胞代谢的主要调节因子。

RB/E2F1 as a Master Regulator of Cancer Cell Metabolism in Advanced Disease.

作者信息

Mandigo Amy C, Yuan Wei, Xu Kexin, Gallagher Peter, Pang Angel, Guan Yi Fang, Shafi Ayesha A, Thangavel Chellappagounder, Sheehan Beshara, Bogdan Denisa, Paschalis Alec, McCann Jennifer J, Laufer Talya S, Gordon Nicolas, Vasilevskaya Irina A, Dylgjeri Emanuela, Chand Saswati N, Schiewer Matthew J, Domingo-Domenech Josep, Den Robert B, Holst Jeff, McCue Peter A, de Bono Johann S, McNair Christopher, Knudsen Karen E

机构信息

Department of Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania.

The Institute of Cancer Research, London, United Kingdom.

出版信息

Cancer Discov. 2021 Sep;11(9):2334-2353. doi: 10.1158/2159-8290.CD-20-1114. Epub 2021 Apr 20.

DOI:10.1158/2159-8290.CD-20-1114
PMID:33879449
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8419081/
Abstract

Loss of the retinoblastoma (RB) tumor suppressor protein is a critical step in reprogramming biological networks that drive cancer progression, although mechanistic insight has been largely limited to the impact of RB loss on cell-cycle regulation. Here, isogenic modeling of RB loss identified disease stage-specific rewiring of E2F1 function, providing the first-in-field mapping of the E2F1 cistrome and transcriptome after RB loss across disease progression. Biochemical and functional assessment using both and models identified an unexpected, prominent role for E2F1 in regulation of redox metabolism after RB loss, driving an increase in the synthesis of the antioxidant glutathione, specific to advanced disease. These E2F1-dependent events resulted in protection from reactive oxygen species in response to therapeutic intervention. On balance, these findings reveal novel pathways through which RB loss promotes cancer progression and highlight potentially new nodes of intervention for treating RB-deficient cancers. SIGNIFICANCE: This study identifies stage-specific consequences of RB loss across cancer progression that have a direct impact on tumor response to clinically utilized therapeutics. The study herein is the first to investigate the effect of RB loss on global metabolic regulation and link RB/E2F1 to redox control in multiple advanced diseases..

摘要

视网膜母细胞瘤(RB)肿瘤抑制蛋白的缺失是重编程驱动癌症进展的生物网络的关键步骤,尽管其机制研究主要局限于RB缺失对细胞周期调控的影响。在此,RB缺失的同基因模型确定了E2F1功能在疾病阶段特异性的重新布线,提供了在疾病进展过程中RB缺失后E2F1顺式作用元件组和转录组的首次领域内图谱。使用两种模型进行的生化和功能评估确定了RB缺失后E2F1在氧化还原代谢调控中出人意料的突出作用,这推动了晚期疾病特有的抗氧化剂谷胱甘肽合成增加。这些E2F1依赖性事件导致在治疗干预时免受活性氧的影响。总体而言,这些发现揭示了RB缺失促进癌症进展的新途径,并突出了治疗RB缺陷型癌症潜在的新干预节点。意义:本研究确定了癌症进展过程中RB缺失的阶段特异性后果,这些后果对肿瘤对临床应用治疗的反应有直接影响。本文的研究首次探讨了RB缺失对整体代谢调控的影响,并将RB/E2F1与多种晚期疾病中的氧化还原控制联系起来。

相似文献

1
RB/E2F1 as a Master Regulator of Cancer Cell Metabolism in Advanced Disease.RB/E2F1作为晚期疾病中癌细胞代谢的主要调节因子。
Cancer Discov. 2021 Sep;11(9):2334-2353. doi: 10.1158/2159-8290.CD-20-1114. Epub 2021 Apr 20.
2
Genomic instability and proliferation/survival pathways in RB1-deficient malignancies.RB1基因缺陷型恶性肿瘤中的基因组不稳定性与增殖/存活通路
Adv Biol Regul. 2017 May;64:20-32. doi: 10.1016/j.jbior.2017.01.002. Epub 2017 Feb 8.
3
Differential impact of RB status on E2F1 reprogramming in human cancer.RB 状态对人类癌症中 E2F1 重编程的差异影响。
J Clin Invest. 2018 Jan 2;128(1):341-358. doi: 10.1172/JCI93566. Epub 2017 Dec 4.
4
TIGAR induces p53-mediated cell-cycle arrest by regulation of RB-E2F1 complex.TIGAR 通过调节 RB-E2F1 复合物诱导 p53 介导的细胞周期停滞。
Br J Cancer. 2012 Jul 24;107(3):516-26. doi: 10.1038/bjc.2012.260. Epub 2012 Jul 10.
5
MicroRNA-598 acts as an inhibitor in retinoblastoma through targeting E2F1 and regulating AKT pathway.miR-598 通过靶向 E2F1 并调节 AKT 通路在视网膜母细胞瘤中发挥抑制作用。
J Cell Biochem. 2020 Mar;121(3):2294-2302. doi: 10.1002/jcb.29453. Epub 2019 Oct 31.
6
The role of the retinoblastoma/E2F1 tumor suppressor pathway in the lesion recognition step of nucleotide excision repair.视网膜母细胞瘤/E2F1肿瘤抑制通路在核苷酸切除修复的损伤识别步骤中的作用。
DNA Repair (Amst). 2009 Jul 4;8(7):795-802. doi: 10.1016/j.dnarep.2009.03.003. Epub 2009 Apr 18.
7
Chromatin remodelers HELLS and UHRF1 mediate the epigenetic deregulation of genes that drive retinoblastoma tumor progression.染色质重塑因子HELLS和UHRF1介导驱动视网膜母细胞瘤肿瘤进展的基因的表观遗传失调。
Oncotarget. 2014 Oct 30;5(20):9594-608. doi: 10.18632/oncotarget.2468.
8
Novel Oncogenic Transcription Factor Cooperation in RB-Deficient Cancer.RB 缺陷型癌症中的新型致癌转录因子合作
Cancer Res. 2022 Jan 15;82(2):221-234. doi: 10.1158/0008-5472.CAN-21-1159. Epub 2021 Oct 8.
9
Combination of oncolytic adenovirus and endostatin inhibits human retinoblastoma in an in vivo mouse model.溶瘤腺病毒与内皮抑素联合抑制体内小鼠模型中的人视网膜母细胞瘤。
Int J Mol Med. 2013 Feb;31(2):377-85. doi: 10.3892/ijmm.2012.1197. Epub 2012 Nov 29.
10
Comparison of the therapeutic effects of lobaplatin and carboplatin on retinoblastoma in vitro and in vivo.比较洛铂和卡铂对体外和体内视网膜母细胞瘤的治疗效果。
Int J Oncol. 2020 Sep;57(3):697-706. doi: 10.3892/ijo.2020.5085. Epub 2020 Jun 22.

引用本文的文献

1
Clonorchis sinensis-driven hepatocarcinogenesis via E2F1-CD24 transcriptional axis: mechanistic and therapeutic implications.华支睾吸虫通过E2F1-CD24转录轴驱动肝癌发生:机制及治疗意义
Parasit Vectors. 2025 Aug 19;18(1):353. doi: 10.1186/s13071-025-06979-6.
2
New frontiers in prostate cancer treatment from systemic therapy to targeted therapy.前列腺癌治疗的新前沿:从全身治疗到靶向治疗
EMBO Mol Med. 2025 Aug 4. doi: 10.1038/s44321-025-00282-8.
3
New Insights into Potential Therapeutic Targets for Neuroendocrine Prostate Cancer: From Bench to Clinic.

本文引用的文献

1
Amino Acid Transporters and Exchangers from the SLC1A Family: Structure, Mechanism and Roles in Physiology and Cancer.SLC1A 家族的氨基酸转运体和交换体:结构、机制以及在生理学和癌症中的作用。
Neurochem Res. 2020 Jun;45(6):1268-1286. doi: 10.1007/s11064-019-02934-x. Epub 2020 Jan 24.
2
Understanding of ROS-Inducing Strategy in Anticancer Therapy.理解 ROS 诱导策略在抗癌治疗中的作用。
Oxid Med Cell Longev. 2019 Dec 18;2019:5381692. doi: 10.1155/2019/5381692. eCollection 2019.
3
Transsulfuration Activity Can Support Cell Growth upon Extracellular Cysteine Limitation.
神经内分泌前列腺癌潜在治疗靶点的新见解:从实验室到临床
Research (Wash D C). 2025 Jul 31;8:0791. doi: 10.34133/research.0791. eCollection 2025.
4
Leucine-rich repeat-containing protein 19 suppresses colorectal cancer by targeting cyclin-dependent kinase 6/E2F1 and remodeling the immune microenvironment.富含亮氨酸重复序列蛋白19通过靶向细胞周期蛋白依赖性激酶6/E2F1和重塑免疫微环境来抑制结直肠癌。
World J Gastroenterol. 2025 Jul 7;31(25):107893. doi: 10.3748/wjg.v31.i25.107893.
5
Establishment and rescue of fibroblast cell lines carrying a nonsense mutation of RB1 by CRISPR-based base editing.通过基于CRISPR的碱基编辑建立并挽救携带RB1基因无义突变的成纤维细胞系
Sci Rep. 2025 Jul 11;15(1):25074. doi: 10.1038/s41598-025-10600-2.
6
Regulation of ferroptosis by transcription factor E2F1.转录因子E2F1对铁死亡的调控
Biochimie. 2025 Jun 25;236:127-137. doi: 10.1016/j.biochi.2025.06.013.
7
Synergistic targeting of cancer cells through simultaneous inhibition of key metabolic enzymes.通过同时抑制关键代谢酶对癌细胞进行协同靶向治疗。
Cell Death Differ. 2025 Jun 23. doi: 10.1038/s41418-025-01532-5.
8
CDK-4 regulates nucleolar size and metabolism at the cost of late-life fitness in C. elegans.细胞周期蛋白依赖性激酶4(CDK-4)以牺牲秀丽隐杆线虫的晚年健康为代价,调节核仁大小和新陈代谢。
Heredity (Edinb). 2025 May 18. doi: 10.1038/s41437-025-00769-7.
9
NAT10-mediated N4-acetylcytosine modification promotes the progression of retinoblastoma by improving the HK1 mRNA stability to enhance glycolysis.NAT10介导的N4-乙酰胞嘧啶修饰通过提高HK1 mRNA稳定性以增强糖酵解来促进视网膜母细胞瘤进展。
Clinics (Sao Paulo). 2025 May 8;80:100678. doi: 10.1016/j.clinsp.2025.100678. eCollection 2025.
10
The interplay between angiogenesis-associated genes and molecular, clinical, and immune features in bladder cancer.膀胱癌中血管生成相关基因与分子、临床及免疫特征之间的相互作用。
Discov Oncol. 2025 Mar 5;16(1):265. doi: 10.1007/s12672-025-01966-w.
转硫活性可在细胞外半胱氨酸限制时支持细胞生长。
Cell Metab. 2019 Nov 5;30(5):865-876.e5. doi: 10.1016/j.cmet.2019.09.009. Epub 2019 Oct 10.
4
BORIS promotes chromatin regulatory interactions in treatment-resistant cancer cells.BORIS 促进治疗抵抗性癌细胞中的染色质调控相互作用。
Nature. 2019 Aug;572(7771):676-680. doi: 10.1038/s41586-019-1472-0. Epub 2019 Aug 7.
5
Unraveling the Potential Role of Glutathione in Multiple Forms of Cell Death in Cancer Therapy.揭示谷胱甘肽在癌症治疗中多种细胞死亡形式中的潜在作用。
Oxid Med Cell Longev. 2019 Jun 10;2019:3150145. doi: 10.1155/2019/3150145. eCollection 2019.
6
Novel RB1-Loss Transcriptomic Signature Is Associated with Poor Clinical Outcomes across Cancer Types.新型 RB1 缺失转录组特征与多种癌症类型的不良临床结局相关。
Clin Cancer Res. 2019 Jul 15;25(14):4290-4299. doi: 10.1158/1078-0432.CCR-19-0404. Epub 2019 Apr 22.
7
Metastatic castration resistant prostate cancer with squamous cell, small cell, and sarcomatoid elements-a clinicopathologic and genomic sequencing-based discussion.转移性去势抵抗性前列腺癌伴鳞、小细胞和肉瘤样成分:基于临床病理和基因组测序的讨论。
Med Oncol. 2019 Feb 2;36(3):27. doi: 10.1007/s12032-019-1250-8.
8
Amino acid transporter SLC7A11/xCT at the crossroads of regulating redox homeostasis and nutrient dependency of cancer.氨基酸转运蛋白 SLC7A11/xCT 在调节氧化还原平衡和肿瘤营养依赖性的十字路口。
Cancer Commun (Lond). 2018 Apr 25;38(1):12. doi: 10.1186/s40880-018-0288-x.
9
MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer.癌症中获得性 CDK4/6 抑制剂耐药导致的 MAPK 依赖。
Clin Cancer Res. 2018 Sep 1;24(17):4201-4214. doi: 10.1158/1078-0432.CCR-18-0410. Epub 2018 May 8.
10
Insights into the Structure, Function, and Ligand Discovery of the Large Neutral Amino Acid Transporter 1, LAT1.解析大中性氨基酸转运蛋白 1(LAT1)的结构、功能和配体发现。
Int J Mol Sci. 2018 Apr 24;19(5):1278. doi: 10.3390/ijms19051278.